[2H3]-Mirtazapine N-Oxide - Names and Identifiers
[2H3]-Mirtazapine N-Oxide - Physico-chemical Properties
Molecular Formula | C17H16D3N3O
|
Molar Mass | 284.370745334 |
Storage Condition | 2-8°C |
[2H3]-Mirtazapine N-Oxide - Introduction
Mirtazapine-d3 N-Oxide(Mirtazapine-d3-N-oxide) is an isotopically labeled compound of the hydrogenated non-classical antidepressant "Mirtazapine. It is a compound in which one of the three hydrogen atoms in "Mirtazapine" (called D-hydrogen) is replaced with deuterium (D).
Mirtazapine-d3 N-Oxide are similar in chemical properties to ordinary Mirtazapine N-Oxide and are white crystalline solids. It is soluble in polar organic solvents, such as ethanol and dimethyl sulfoxide, but insoluble in water.
In practical application, Mirtazapine-d3 N-Oxide is mainly used as an internal standard in pharmacokinetics and Pharmacometabolomics research. By adding a deuterium label to the target drug (Mirtazapine), the process of metabolism and elimination of this drug in the body can be tracked and measured, and its pharmacokinetic properties can be better understood.
The method for preparing Mirtazapine-d3 N-Oxide usually involves reacting Mirtazapine with an appropriate amount of oxidizing agent to obtain N-so-and-so compound, which is then reacted with deuterated acid to prepare Mirtazapine-d3 N-Oxide. The specific preparation method may depend on the experimental conditions and reaction requirements, and these details may need to be obtained in the specific research literature.
Regarding its safety information, according to the available information, there are no detailed public reports on the toxicity and safety of Mirtazapine-d3 N-Oxide. However, since it is an isotopically labeled compound of Mirtazapine, its safety can be inferred based on the safety and toxicity data of Mirtazapine. However, for specific uses and applications, it needs to be carried out under suitable laboratory conditions and follow relevant laboratory safety procedures and regulations. At the same time, ethical regulations and legal requirements should be observed when conducting pharmacokinetic studies in animals or humans.
Last Update:2024-04-09 21:54:55